[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

4 clusters · 16 sources · 41 days · First seen · Last updated

Brazil HIV prevention technology incorporation

Overview

Brazil’s National Commission for the Incorporation of Technologies in the SUS (Conitec) has issued a preliminary favorable recommendation to include injectable cabotegravir in the Unified Health System (SUS). This long-acting medication, produced by GSK, is intended to expand HIV prevention options rather than replace existing oral Pre-Exposure Prophylaxis (PrEP).

The Ministry of Health intends to prioritize the injectable version for highly vulnerable individuals who encounter social or logistical barriers to the consistent use of oral PrEP. Unlike the daily oral PrEP pills currently used by over 150,000 people in Brazil, this injectable version offers protection that lasts for two months. The administration schedule involves monthly injections for the first two months, followed by doses every two months. Clinical studies indicate a protection rate exceeding 99%.

While official estimates suggest the drug could arrive in the second half of 2026, GSK officials have indicated that if a positive recommendation is received from Conitec in October, they will attempt to make the medication available as early as this year. The drug has already received approval from Anvisa for three years.

Entities

SUS · Conitec · Ministry of Health · Sistema Único de Saúde · Lívia Almeida Dutra

Timeline

  1. [HEALTH] 2 sources
    Brazil evaluates adding weight loss drugs and injectable HIV prevention to SUS

    Brazil's Ministry of Health is seeking to incorporate GLP-1 weight loss medications and injectable HIV prevention (Cabotegravir) into the public health system (SUS).

  2. [HEALTH] 3 sources
    Brazil's SUS may adopt long-acting HIV prevention injectable

    Brazil's SUS may adopt GSK's long-acting injectable HIV prevention drug, cabotegravir, potentially as early as this year if approved by Conitec, offering protection for up to two months per dose.

  3. [HEALTH] 2 sources
    Brazil considers injectable HIV prevention for SUS

    Brazil is considering the incorporation of injectable cabotegravir into the SUS to expand HIV prevention, prioritizing vulnerable populations who struggle to use oral PrEP.

  4. [HEALTH] 9 sources
    Brazil's SUS increases Natalizumab distribution for multiple sclerosis

    A study by Einstein Hospital shows a 44.5% increase in Natalizumab distribution via Brazil's SUS from 2019 to 2023, following updated clinical guidelines for multiple sclerosis treatment.

Sources

acessa.com · anf.org.br · atarde.com.br · chicoterra.com · chumbogrossomanaus.com.br · correiodecarajas.com.br · grnews.com.br · imprensapublica.com.br · jornale.com.br · jornalenoticias.com.br · mrnews.com.br · oglobo.globo.com · onortao.com.br · paranashop.com.br · polemicaparaiba.com.br · tribunadaserra.com.br

This summary has been updated 2 times: see revision history